All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MPN Hub spoke to Raajit K. Rampal, Memorial Sloan Kettering Cancer Center, New York, US. We asked: How should genomic assessment in myelofibrosis be performed?
How should genomic assessment in MF be performed?
An increased understanding of the genetic drivers of MPN has been observed over the past decade, and several mutations have been associated with differential prognosis and response to treatment. Therefore, Raajit Rampal suggests that patients should undergo a full genetic assessment at the time of initial evaluation as standard of care in the MPN setting.
Subscribe to get the best content related to MPN delivered to your inbox